EU: Fed or fasting conditions for BE study [Design Issues]

posted by Farmacevt – North Macedonia, 2021-09-24 17:47 (501 d 05:15 ago) – Posting: # 22595
Views: 1,322

Dear all,

Please advise if the BE study for EU submission should be performed under fed or fast condition for the following case:

Fix dose combination product, for one mono-component of the FDC there is a product specific guideline in which it is recommended that the BE study should be performed under fasting condition, and for the second mono-component there is no product specific guideline.

According to the SmPC of the reference product (FDC) intended for the BE study it is stated: FDC should be given twice daily with meals to reduce the gastrointestinal adverse reactions associated with the second mono-component (for which we do not have product specific guideline).

For the first mono-component, co-administration of a high-fat meal has no effect on the pharmacokinetics, and this mono-component may be administered with or without food.

For the second mono-component for which we do not have product specific guideline, it is known that Food decreases the extent and slightly delays the absorption.

What is the most appropriate condition for performing the BE study in this situation, fed or fasting :-) ?

Thank you,


Edit: Category and subject line changed; see also this post #1 and #2[Helmut]

Complete thread:

UA Flag
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
14 visitors (0 registered, 14 guests [including 7 identified bots]).
Forum time: 22:03 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz